VAM
NERV icon

Visium Asset Management’s Minerva Neurosciences NERV Stock Holding History

Visium Asset Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,482
Closed -$203K – 130
2016
Q2 		$203K Buy
+2,482
New +$158K 0.01% 321

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Visium Asset Management's NERV Position: Q3 2016 in Review

Visium Asset Management sold out of Minerva Neurosciences (NERV) in Q3 2016, closing a stake of 2,482 shares — an estimated $203K sold.

Visium Asset Management first reported a position in NERV in Q2 2016 and held it in 1 quarter. The position peaked at $203K in Q2 2016. 67 funds tracked by Wall St. Rank hold NERV as of Q3 2016.

  • Visium Asset Management reported no remaining Minerva Neurosciences position as of Q3 2016 after selling out during the quarter.
  • Visium Asset Management sold 2,482 Minerva Neurosciences shares in Q3 2016, an estimated $203K.
  • Visium Asset Management first reported a position in Minerva Neurosciences in Q2 2016 and held it in 1 quarter.
  • Visium Asset Management's Minerva Neurosciences position peaked at $203K in Q2 2016.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2016.

Based on Visium Asset Management's 13F filing for Q3 2016.